Kane Biotech Inc. KNE

Board Chair Philip Renaud, leading wound-care surgeon Dr. John C. Lantis and Interim CEO Dr. Robert Huizinga to discuss Kane’s commercial progress, clinical relevance and operational prioritiesWINNIPEG, Manitoba, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”), a biotechnology company commercializing and developing technologies and products that address microbial biofilms, today announced that it will host a virtual Commercial Update on

Agreement broadens access to revyve® advanced wound care products through an established Canadian medical supply distributorWINNIPEG, Manitoba, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) is pleased to announce that it has entered into a non-exclusive distribution agreement with Ontario Medical Supply Inc. ("OMS"), an Ottawa-based medical supply distributor serving the Canadian market. U.S. FDA 510(k) cleared and Health Canada approv

WINNIPEG, Manitoba, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its second quarter 2026 financial results. Second Quarter 2026 Financial Highlights: Total revenue for the three months ended June 30, 2026 was $8,143 compared to $27,997 for the three months ended June 30, 2025. Revenue in the second quarter of 2026 reflected the Company’s continued early-stage commercialization of its revyve® product line, including init

Presentation addressed potential applications in prolonged field care and military wound management settingsWINNIPEG, Manitoba, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today that research regarding its revyve antimicrobial wound care technology was presented at the Military Health System Research Symposium (MHSRS), held August 3-5, 2026 in Kissimmee, Florida. This release follows completion of Kane’s post-conference revi

DNA Advisors brings expertise in capital markets, strategic transactions, partnerships, and growth initiativesWINNIPEG, Manitoba, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane” or the “Company”), announces that it has retained DNA Advisors Inc. (“DNA Advisors”) as its exclusive financial advisor to support a comprehensive review of strategic opportunities aimed at enhancing shareholder value and advancing the Company's long-term growth objectives. The strategic review p

WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on June 24, 2026. A total of 83,622,028 common shares were represented at the Meeting, representing approximately 46% of the Company’s issued and outstanding common shares (“Common Shares”) as of the record date of the Meeting. All matters voted upon at the Meeting were approved by shar

WINNIPEG, Manitoba, May 28, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its first quarter 2026 financial results. First Quarter 2026 Financial Highlights: Total revenue for the three months ended March 31, 2026 was $43,218 compared to $412,513 in three months ended March 31, 2025. Revenue in the period reflects early-stage commercialization of revyve wound gel alongside the liquidation of the Company’s DermaKB® product line. Th

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, May 26, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has increased the size of its previously announced non-brokered private placement offering (the “Offering”) of units of the Company (“Units”) from up to $1,000,000 to $1,160,000 and has subsequently completed such Offering. The increase in the size of the Offering

Case study presented highlighted clinical experience with revyve® in complex wound careWINNIPEG, Manitoba, May 13, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announced today its participation in the World Council of Enterostomal Therapists and Nurses Specialized in Wound, Ostomy and Continence Canada (“WCET–NSWOCC”) 2026 Joint Congress, held April 24–28, 2026, in Vancouver, British Columbia. The WCET–NSWOCC Joint Congress brings together glob

>20 year‑old venous leg ulcers show dramatic healing and pain elimination with revyveThermoreversible revyve transforms deep tunneling wound care, delivering 90% wound volume reductionrevyve rapidly normalizes chronic wound pH, driving accelerated healing in weeks WINNIPEG, Manitoba, April 16, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Dr. Miloslav Sailer, External R&D Leader, presented at the Symposium on Advanced Wound

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Hydrogel Wound Dressing Market size & share revenue was valued at approximately USD 982 Million in 2025 and is expected to reach USD 1,057 Million in 2026 and is expected to reach around USD 1656 Million by 2035, at a CAGR of 4.4% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are 3M, Smith & Nephew, Conva